BiolisiintsDMARDit
BiolisiintsDMARDit is a descriptive name sometimes used to denote a conceptual or developmental biologic disease-modifying anti-rheumatic drug (DMARD), particularly in contexts discussing biosimilar or next-generation biologic immunomodulators. The term is not a standardized international nonproprietary name (INN) for a single marketed product, but may appear in literature or proposals to describe agents intended to replicate or improve effects of established biologic DMARDs.
Agents described by this label are typically monoclonal antibodies, antibody fragments or fusion proteins that target
In development and clinical use, such biologic DMARDs are evaluated through phased clinical trials for efficacy,
Safety considerations mirror those for established biologic DMARDs and include increased risk of infection, potential injection-